Compugen Ltd. (NASDAQ:CGEN) spotted trading -7.58% off 52-week high price. On the other end, the stock has been noted 333.33% away from the low price over the last 52-weeks. The stock changed 1.63% to recent value of $11.83. The stock transacted 1099012 shares during most recent day however it has an average volume of 580.64K shares. The company has 69.16M of outstanding shares and 67.78M shares were floated in the market.
On March 11, 2020, Compugen Ltd. (NASDAQ:CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, revealed that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares. In connection with the offering, Compugen expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company’s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen’s antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company’s therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen’s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA. Compugen’s shares are listed on the Nasdaq Global Market under the ticker symbol CGEN and on the Tel Aviv Stock Exchange.
Its earnings per share (EPS) expected to touch remained -5.10% for this year.
According to the most recent quarter its current ratio was 6.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 24.87% from the mean of 20 days, 51.12% from mean of 50 days SMA and performed 130.29% from mean of 200 days price. Company’s performance for the week was 20.10%, 37.88% for month and YTD performance remained 98.49%.